2021 American Transplant Congress
Rabbit Anti-thymocyte Globulin Induction Dosing Strategies in a High-risk Kidney Transplant Population
Pharmacy, CHI Baylor St. Luke's Medical Center, Houston, TX
*Purpose: The objective of this retrospective observational study is to compare the safety and efficacy of two dosing strategies, rabbit anti-thymocyte globulin (rATG) at a…2021 American Transplant Congress
First Promising Results of CIAT: A New Kidney Exchange Program for Difficult-to-match Patients
*Purpose: Computerised Integration of Alternative Transplantation (CIAT) programs was developed to increase the chances of highly immunized (HI) and longwaiting (LW) kidney transplant candidates. CIAT…2020 American Transplant Congress
Outcomes of HLAi Transplant in CPRA 98-100 after Desensitization: Single Center Experience
1Cedars Sinai Medical Ctr, Los Angeles, CA, 2Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: The new KAS implementation aimed at increasing equity in organ allocation for broadly sensitized (HS) patients. However, recent data shows that for the most…2020 American Transplant Congress
Third and Fourth Kidney Re-Transplants: A 20-Year Single Centre Experience
*Purpose: Re-transplantation may be associated with management dilemmas including repeat allocation of limited kidney allografts to same individuals in the face of an increasing waiting…2020 American Transplant Congress
Anti-HLA IgM Antibodies are Unaffected by Imlifidase (IdeS) Treatment
*Purpose: The immunoglobulin G (IgG)-degrading cysteine protease, imlifidase (IdeS) is an IgG endopeptidase under development as a rapid desensitization treatment in kidney transplantation. Imlifidase is…2020 American Transplant Congress
Outcomes of Post-Transplant Desensitization in High Immunological Risk Deceased Donor Kidney Transplant Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: The kidney allocation system (KAS) was changed in 2015 to increase access to transplants for highly sensitized patients. However, recent data suggests that even…2020 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up
*Purpose: IL-6 mediates inflammation and activation of T-cells, B-cells & plasma cells. Thus, IL-6 may represent an important target for desensitization (DES). Here we report…2020 American Transplant Congress
Infectious Complications in Elderly Kidney Transplant Recipients Undergoing Desensitization
Cedars Sinai Medical Center, West Hollywood, CA
*Purpose: Data is limited on the impact of desensitization on infectious complications in elderly kidney transplant (KT) recipients. We examined infectious complications in elderly KT…2020 American Transplant Congress
Preformed Anti-HLA Donor-Specific Antibodies Immunological Risk Assessment: The Importance of HLA Antibody Locus-Specificity
*Purpose: The screening of preformed donor-specific HLA antibodies (pfDSA) by single antigen bead assays has increased the complexity of pre-transplant patient risk stratification. We evaluated…2020 American Transplant Congress
Feasibility and Limitations of Desensitization Therapy in Highly Sensitized Pediatric ESRD Patients: A Single-Center Experience
*Purpose: There are a growing number of pediatric (peds) patients (pts) awaiting renal transplantation (tx) who are considered highly sensitized (HS). We report long-term outcomes…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 15
- Next Page »